Catheter Precision (VTAK) EBITDA (2017 - 2026)

Catheter Precision (VTAK) has 10 years of EBITDA data on file, last reported at -$2.3 million in Q1 2026.

• On a quarterly basis, EBITDA rose 35.16% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was -$19.9 million, a 62.97% decrease from a year earlier, with the FY2025 full-year figure at -$21.1 million, down 88.05% from the prior year.
• EBITDA for Q1 2026 stood at -$2.3 million, up from -$9.9 million in the prior quarter.
• Over the last five years, EBITDA for VTAK reached as high as -$2.3 million in Q1 2026 and fell as low as -$66.5 million in Q1 2023.
• Historically, EBITDA has averaged -$8.2 million across 5 years, with a median of -$3.6 million in 2025.
• Across the five-year window, EBITDA tumbled 1108.14% in 2023 and jumped 96.07% in 2024, its largest moves.
• Year by year, EBITDA stood at -$8.2 million in 2022, then soared by 68.39% to -$2.6 million in 2023, then decreased by 17.48% to -$3.1 million in 2024, then slumped by 223.21% to -$9.9 million in 2025, then jumped by 76.49% to -$2.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$2.3 million in Q1 2026, -$9.9 million in Q4 2025, and -$3.0 million in Q3 2025.